Enanta Pharma (ENTA) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
August 7, 2018 4:01 PM EDTWebcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $57.3 million, a quarter-to-quarter increase of 30% Net income was $20.3 million, or $0.97 per diluted common share Preliminary Phase 1 results demonstrate that RSV candidate EDP-938 was generally safe and well tolerated and support its progression to Phase 2 Cash and marketable securities totaled $295.5 million at June 30, 2018
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a... More
